DXCM241213C59000
- 18.50
- 0.000.00%
DexCom Newsroom
Nephron Research Adjusts Price Target on DexCom to $125 From $145
DexCom Is Maintained at Buy by Citigroup
10 BofA U.S. Options Overwriting Ideas
Unusual Options Activity: ACI, FTI and Others Attract Market Bets, ACI V/OI Ratio Reaches 75.0
EST Dec 11th Morning Delivery - In the last two hours of trading, 9 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
DexCom Is Maintained at Overweight by Wells Fargo
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Raises Target Price to $94
Express News | Dexcom Inc : Citigroup Raises Target Price to $91 From $85
Express News | Dexcom, Inc. : Wells Fargo Raises Target Price to $94 From $90
BofA Securities Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $90
Dexcom Shares up as Diabetes Association Updates Guidelines
BofA Securities Maintains DexCom(DXCM.US) With Buy Rating, Announces Target Price $90
Watching Shares Of DexCom; Traders Circulating Note American Diabetes Association Updates Standards To Recommend Continuous Glucose Monitoring For Non-Insulin Type 2 Diabetes Patients, Paving Way For Broader Coverage And Market Growth; Bank Of America...
Express News | Tandem T:Slim X2 Insulin Pump Now Compatible With Dexcom G7 Cgm in Canada
Tandem T:slim X2 Insulin Pump Now Compatible With Dexcom G7 CGM in Canada
Is DexCom Stock Underperforming the Nasdaq?
DexCom Is Maintained at Buy by Canaccord Genuity
DexCom Analyst Ratings
CCORF Maintains DexCom(DXCM.US) With Buy Rating, Raises Target Price to $99
Express News | Dexcom Inc : Canaccord Genuity Raises Target Price to $99 From $89
Investing in DexCom (NASDAQ:DXCM) Five Years Ago Would Have Delivered You a 56% Gain